STAAR SURGICAL CO

Insider buys signal confidence in STAAR Surgical’s high‑margin ophthalmic implants, pointing to potential growth and a bullish stock outlook.

STAAR Surgical insider buys options—signaling confidence in its expanding vision‑care lineup and potential upside for long‑term investors.

Insider options boost STAAR Surgical’s confidence: board moves hint at future growth in vision‑care devices—investors weigh upside amid market volatility.

Insider buying at STAAR Surgical signals confidence in upcoming eye‑care product launches, hinting at a near‑term earnings boost and potential stock recovery.

STAAR Surgical insiders buy 20,787 RSUs amid leadership shake‑up—signals confidence and potential upside for shareholders.

STAAR Surgical insider stability signals potential upside: director Le Buhn keeps shares, Broadwood adds millions, while a high‑margin implant pipeline could spark a rebound amid a declining stock and negative P/E.

Insider buying at STAAR Surgical signals confidence amid volatility—Jiang Wei and Broadwood Partners stake big shares, hinting at a rebound in visual‑implant sales.

Broadwood Partners keeps buying STAAR Surgical shares, boosting its stake to 1.4% while market price hovers near $22—what does this mean for investors?

Broadwood Partners’ new stake in STAAR Surgical signals a potential undervaluation, as the firm backs the company’s return to core ophthalmic devices after a failed Alcon merger.